A drug that can prevent or slow down aging will be the greatest invention in the medicine world. Dr. Mikhail Blagosklonny suggests the use of Rapamycin, a drug that is administered to cancer patients, to be used for prolonging life. The drug is safe for oral intake daily and no effects have been noted. That is the reason it is used with cancer patients. Michael Hall discovered rapamycin and realized it could be used to treat autoimmunity, cancer, metabolic disorder and cardiovascular disease. Researchers say that the drug can be used to delay aging and improve the health of the elderly. Rapamycin delays aging by boosting the immune system. Follow Mikhail on Google Scholar
Impact on the success of anti-aging drug
People die from age-related diseases and if aging is prolonged, then the diseases will also be postponed. In this case, does it mean that people will not die? That may not be necessarily true, humans will not be immortal as other illness will arise that will cause death and the effect of prolonging life can also bring about syndromes that will eventually lead to fatalities. Currently, the post-aging syndromes are not known so they can not be recognized; the proof will only be available if it happens. There are other causes of death like the external causes like infections. Therefore, even if aging-related diseases are eliminated people can still die from the external cause.
What is available now is procedures that allow people to live longer despite age-related diseases, a good example being by-pass surgery. Now it is up to researchers to concentrate on post-aging syndromes so that when trials on Rapamycin as an anti-aging drug is allowed, they will have the solution to the post-aging syndrome.
About Mikhail Blagosklonny
Mikhail Blagosklonny is an oncologist professor at the Roswell Park Cancer Institute since 2009. Before then he was an associate professor of medicine at New York College and a senior scientist at Ordway Research Institute. His experience in research and teaching has made him an excellent professor. He still has a great passion for research and his main focus are cancer, targeted cancer therapies that guard the healthy cells against damage, anti-aging drugs and underlying mechanisms of aging.
Other than research and being a professor, Dr. Blagosklonny is the chief editor of Oncotarget and Cell Cycle, an associate editor for cancer biology, therapy and PLOS ONE. He is also part of the board in Cell Death and Differentiation. Mikhail has written over three hundred reviews, book chapters and research articles throughout his career. Visit classroomvoices.org to read more about Mikhail.
Mikhail Blagosklonny earned a medical degree in Internal Medicine at the First Pavlov State Medical University of St. Petersburg and later a Ph.D. in Experimental Medicine and Cardiology from the same institution. Mikhail has a keen interest in cancer and aging. He believes aging can be controlled and cancer can be eliminated. His achievements have seen him being rank among top oncology researchers in the world. At the end of the day, Mikhail Blagosklonny wants to see disease-free community; that is the drive of hard work.